Recent Investments/Transactions

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan”) today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the “Merger Agreement”) regarding a business combination with KE Sdn. Bhd. (“KE”).

BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025

David Lazar agrees to invest $3.1 million in Preferred Stock and becomes Interim CEO BERKELEY HEIGHTS, N.J., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") today announced that the Company entered into a securities purchase agreement (“Agreement”) with investor David Lazar (“Lazar”)..

MIAMI BEACH, FL / ACCESSWIRE / December 13, 2024 / LQR House Inc. (the "Company" or "LQR House") (NASDAQ:LQR), a niche e-commerce platform specializing in the spirits and beverage industry, today announced that its shares of common stock will begin trading under the new ticker symbol "YHC" on the Nasdaq Capital Market prior to the market open on December 16, 2024.

LQR House (NASDAQ:LQR) said on Wednesday that it has entered into a securities purchase agreement with activist investor David Lazar. Under the agreement, Lazar has committed to providing $3M in funding to LQR House.

NEW YORK, Jan. 30, 2024 /PRNewswire/ -- David E. Lazar, an experienced private investor, today filed a Schedule 13D announcing his acquisition of 2,000,000 shares of Series A Convertible Preferred Stock ("Series A Preferred Stock") of Minim, Inc. ("Minim" or the "Company"). Each share of Series A Preferred Stock is convertible into 1.4 shares of the Company's common stock ("Common Stock").

Titan Pharmaceuticals shares rallied after the company entered into an agreement to combine with KE Sdn. Bhd. in a reverse merger .Shares in premarket trading on Tuesday more than doubled to $10.38.

NEW YORK, June 10, 2022 (GLOBE NEWSWIRE) -- David E. Lazar, Chief Executive Officer of Activist Investing LLC (together with its affiliates, “Activist Investing” or “we”), one of the largest stockholders of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“TTNP” or the “Company”) with 9.9% of the Company’s outstanding shares, today issued the following statement:

ROCKVILLE, Md., March 25, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), announced today that the Company entered into a securities purchase agreement with David E. Lazar, an experienced private investor, pursuant to which he will acquire 3,000,000 shares of Series E Convertible Preferred Stock (“Series E Preferred Stock”) of the Company at a price of $1.00 per share for aggregate gross proceeds of $3.0 million.

Shares of Minim rose after investor David E. Lazar agreed to buy 2 million preferred shares of the provider of WiFi security software.

SAN FRANCISCO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today that it has entered into a definitive securities purchase agreement (the “Purchase Agreement”) with The Sire Group Ltd. (“Sire Group”) for the sale of the Company’s newly designated Series AA Convertible Preferred Stock (the “Preferred Stock”).